MASH / NASH (Fatty Liver Disease) Clinical Trials near Dallas, TX
16 studies for MASH / NASH (Fatty Liver Disease) are recruiting at 68 sites within 50 miles of Dallas, Texas, according to ClinicalTrials.gov data processed .
Distances are city-level approximations. See all MASH / NASH (Fatty Liver Disease) trials in the US or all trials near Dallas.
Recruiting now
MASH / NASH (Fatty Liver Disease) studies enrolling near Dallas
- LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: GI Alliance Research - Dallas (Dallas, TX); North Texas Research Institute - Dallas (Dallas, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 12 sites within 50 mi
- LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: GI Alliance Research - Dallas (Dallas, TX); North Texas Research Institute - Dallas (Dallas, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 7 sites within 50 mi
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716
- Phase 3
- Ages 18 to 80 years
- Sex: All
Nearest sites: Akero Clinical Study Site (Dallas, TX); Akero Clinical Study Site (Dallas, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 6 sites within 50 mi
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314
- Phase 3
- Ages 18 to 80 years
- Sex: All
Nearest sites: Akero Clinical Study Site (Dallas, TX); Akero Clinical Study Site (Dallas, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
NCT07221227
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest sites: GSK Investigational Site (Dallas, TX); GSK Investigational Site (Irving, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 4 sites within 50 mi
- A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
NCT05519475
- Phase 2
- Ages 18 to 75 years
- Sex: All
Nearest sites: Methodist Dallas Medical Center (Dallas, TX); GI Alliance Research (Fort Worth, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
NCT07221188
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest sites: GSK Investigational Site (Dallas, TX); GSK Investigational Site (DeSoto, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07701993
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest sites: GSK Investigational Site (Dallas, TX); GSK Investigational Site (Arlington, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07704892
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest sites: GSK Investigational Site (Dallas, TX); GSK Investigational Site (Arlington, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 2 sites within 50 mi
- Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
NCT06225193
- Observational
- Ages 18 years and older
- Sex: All
Nearest site: Methodist Dallas Medical Center (Dallas, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043
- Phase 2
- Ages 18 to 75 years
- Sex: All
Nearest site: GSK Investigational Site (Dallas, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601
- Phase 2
- Ages 18 to 75 years
- Sex: All
Nearest site: Dallas Methodist (Dallas, TX)
- Distance to nearest recruiting site
- <1 mi (city-level)
- Recruiting sites
- 1 site within 50 mi
- A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169
- Phase 3
- Ages 18 to 80 years
- Sex: All
Nearest sites: 89bio Clinical Study Site (Farmers Branch, TX); 89bio Clinical Study Site (Garland, TX)
- Distance to nearest recruiting site
- ~11 mi (city-level)
- Recruiting sites
- 7 sites within 50 mi
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028
- Phase 3
- Ages 18 years and older
- Sex: All
Nearest sites: Dallas Research Institute (Farmers Branch, TX); Southern Endocrinology Associates (Mesquite, TX)
- Distance to nearest recruiting site
- ~11 mi (city-level)
- Recruiting sites
- 7 sites within 50 mi
- A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374
- Phase 3
- Ages 18 to 75 years
- Sex: All
Nearest sites: 89bio Clinical Study Site (Farmers Branch, TX); 89bio Clinical Study Site (DeSoto, TX)
- Distance to nearest recruiting site
- ~11 mi (city-level)
- Recruiting sites
- 5 sites within 50 mi
- A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07288138
- Phase 2
- Ages 18 to 75 years
- Sex: All
Nearest sites: Dallas Research Institute, LLC (Farmers Branch, TX); GI Alliance Digestive Health Associates of Texas - Garland (Garland, TX)
- Distance to nearest recruiting site
- ~11 mi (city-level)
- Recruiting sites
- 4 sites within 50 mi
FAQ
Common questions
What is a clinical trial?
Is there compensation for joining a MASH / NASH (Fatty Liver Disease) clinical trial?
How do I check if I'm eligible?
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.